We have shown that the downregulation of GATA3 in breast cancer can be controlled by an aberrant activation of DNMT3B, which induces aberrant methylation in the promoter region of GATA3, in the absence of deleterious somatic alterations. The gene discussed is GATA3; the disease is breast carcinoma.